KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest & Investment Income (2019 - 2025)

Historic Interest & Investment Income for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $6.9 million.

  • Royalty Pharma's Interest & Investment Income fell 6057.23% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year decrease of 2064.23%. This contributed to the annual value of $47.3 million for FY2024, which is 3451.05% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Interest & Investment Income is $6.9 million, which was down 6057.23% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Interest & Investment Income registered a high of $43.9 million during Q4 2022, and its lowest value of $6.5 million during Q4 2023.
  • In the last 5 years, Royalty Pharma's Interest & Investment Income had a median value of $12.3 million in 2021 and averaged $14.6 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first skyrocketed by 67258.98% in 2021, then tumbled by 8517.78% in 2023.
  • Royalty Pharma's Interest & Investment Income (Quarter) stood at $10.6 million in 2021, then surged by 312.19% to $43.9 million in 2022, then crashed by 85.18% to $6.5 million in 2023, then skyrocketed by 39.03% to $9.0 million in 2024, then decreased by 23.61% to $6.9 million in 2025.
  • Its Interest & Investment Income stands at $6.9 million for Q3 2025, versus $8.3 million for Q2 2025 and $11.3 million for Q1 2025.